Objective To assess the effectiveness and safety of irbesartan for hypertensive patients with hyperuricaemia.
Methods The databases such as The Cochrane Library (Issue 2, 2010), MEDLINE (by the end of April 2010), SCI (by the end of April 2010), CBM (by the end of April 2010) and CNKI (by the end of April 2010) were searched to collected randomized controlled trails (RCTs) on irbesartan for hypertensive combined with hyperuricaemia. Studies were screened according to the inclusion and exclusion criteria; data were extracted; the methodological quality was evaluated; and meta-analyses were conducted by using RevMan 5.0.0 software.
Results Nine studies involving 977 patients were included. The results of meta-analyses showed that compared with the control group, irbesartan was superior in decreasing serum uric acid (SUA) (MD=57.12, 95%CI 16.08 to 98.15, P=0.006); it was similar in controlling blood pressure (Systolic pressure: MD= –0.24, 95%CI –2.19 to 1.71, P=0.81; Diastolic pressure: MD=0.46, 95%CI –1.58 to 2.50, P=0.66), and lower in the incidence rate of adverse reaction (RR=0.07, 95%CI 0.02 to 0.24, P=0.000 1).
Conclusion The study suggests that irbesartan is effective and safe to control blood pressure and decrease serum uric acid for hypertensive patients with hyperuricaemia. But because all nine included studies are graded C in quality, the conclusion still needs to be further verified by long-term, large scale and high quality studies.
Citation：
WU Fengbo,ZHAN Mei,TANG Yao. Irbesartan for Hypertensive Patients with Hyperuricaemia: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2011, 11(11): 1290-1294. doi: 10.7507/1672-2531.20110218
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
2 Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences.
J Hypertens Suppl
, 2002, 20(5): S29-S31.
|
| 2. |
10 Dang A, Zhang Y, Liu G,
et al
. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
J Hum Hypertens
, 2006, 20(1): 45-50.
|
| 3. |
13 Hoieggen A, Alderman MH, Kjeldsen SE,
et al
. The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Kidney Int
, 2004, 65(3): 1041-1049.
|
| 4. |
高昌静, 蒋永高, 唐振兰. 安徽39824例健康体检者高尿酸血症流行病学分析. 实用医学杂志, 2008, 24(20): 3589.
|
| 5. |
Higgins JPT, Green S, Editors. Cochrane handbook for systematic reviews of interventions: version 5.0.1 Cochrane Collaboration, 2008.
|
| 6. |
邓红亮, 厄贝沙坦联合氨氯地平治疗老年中重度高血压伴高尿酸血症34例. 山东医药, 2009, 49(50): 103.
|
| 7. |
吴慧咏, 胡荣树. 厄贝沙坦与雷米普利治疗高血压合并高尿酸血症的疗效比较. 临床荟萃, 2006, 21(21): 1573-1574.
|
| 8. |
郭明拴, 于静, 陈绍宇. 厄贝沙坦治疗高血压病并高尿酸血症疗效观察. 中国误诊学杂志, 2006, 6(9): 1683-1684.
|
| 9. |
郭利平. 厄贝沙坦治疗高血压合并高尿酸血症90例疗效观察. 中华实用诊断与治疗杂志, 2009, 23(10): 1013-1014.
|
| 10. |
赵锡荣, 程卫兵. 厄贝沙坦治疗中老年高血压合并高尿酸血症的临床分析. 中华初级卫生保健, 2008, 22(11): 85-86.
|
| 11. |
陈宇宁, 曹恒献. 伊贝沙坦治疗高血压并发高尿酸血症的临床观察. 中国基层医药, 2003, 10(12): 1268-1269.
|
| 12. |
张玉东, 兰婷. 伊贝沙坦对高血压病伴高尿酸血症的干预作用. 心血管康复医学杂志, 2008, 17(1): 65-67.
|
| 13. |
付华, 陈建彬, 李星涛. 伊贝沙坦和咪达普利对原发性高血压患者血清尿酸和血脂代谢的影响. 临床荟萃, 2004, 19(20): 1172-1173.
|
- 1. 2 Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences.
J Hypertens Suppl
, 2002, 20(5): S29-S31.
- 2. 10 Dang A, Zhang Y, Liu G,
et al
. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
J Hum Hypertens
, 2006, 20(1): 45-50.
- 3. 13 Hoieggen A, Alderman MH, Kjeldsen SE,
et al
. The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Kidney Int
, 2004, 65(3): 1041-1049.
- 4. 高昌静, 蒋永高, 唐振兰. 安徽39824例健康体检者高尿酸血症流行病学分析. 实用医学杂志, 2008, 24(20): 3589.
- 5. Higgins JPT, Green S, Editors. Cochrane handbook for systematic reviews of interventions: version 5.0.1 Cochrane Collaboration, 2008.
- 6. 邓红亮, 厄贝沙坦联合氨氯地平治疗老年中重度高血压伴高尿酸血症34例. 山东医药, 2009, 49(50): 103.
- 7. 吴慧咏, 胡荣树. 厄贝沙坦与雷米普利治疗高血压合并高尿酸血症的疗效比较. 临床荟萃, 2006, 21(21): 1573-1574.
- 8. 郭明拴, 于静, 陈绍宇. 厄贝沙坦治疗高血压病并高尿酸血症疗效观察. 中国误诊学杂志, 2006, 6(9): 1683-1684.
- 9. 郭利平. 厄贝沙坦治疗高血压合并高尿酸血症90例疗效观察. 中华实用诊断与治疗杂志, 2009, 23(10): 1013-1014.
- 10. 赵锡荣, 程卫兵. 厄贝沙坦治疗中老年高血压合并高尿酸血症的临床分析. 中华初级卫生保健, 2008, 22(11): 85-86.
- 11. 陈宇宁, 曹恒献. 伊贝沙坦治疗高血压并发高尿酸血症的临床观察. 中国基层医药, 2003, 10(12): 1268-1269.
- 12. 张玉东, 兰婷. 伊贝沙坦对高血压病伴高尿酸血症的干预作用. 心血管康复医学杂志, 2008, 17(1): 65-67.
- 13. 付华, 陈建彬, 李星涛. 伊贝沙坦和咪达普利对原发性高血压患者血清尿酸和血脂代谢的影响. 临床荟萃, 2004, 19(20): 1172-1173.
Journal type citation(3)
| 1. | 梁原浩，张翼翔，彭盛昕，肖文珊，刘垒. 超声引导单通道内镜下松解腕横韧带治疗腕管综合征应用分析. 医学影像学杂志. 2024(03): 90-93 .  Baidu Scholar | |
| 2. | 罗建，谭雅菲，黄小虎，聂桂峰，翟雪键，辛杰. 腕管镜及改良小切口松解法治疗糖尿病腕管综合征的疗效分析. 安徽医药. 2017(12): 2233-2237 . Baidu Scholar | |
| 3. | 李佩贤，石玮. 关节镜下腕横韧带切开术治疗迟发性正中神经麻痹的创伤及安全性分析. 浙江创伤外科. 2017(01): 29-30 . Baidu Scholar | |
Other types of references(1)
| 1. | 吕晓雅. 针刀治疗寒湿痹阻型腕部正中神经卡压综合征的临床观察[D]. 山东中医药大学. 2023. Baidu Scholar | |
